115 related articles for article (PubMed ID: 18339473)
1. Editorial comment on: preoperative serum sex hormone-binding globulin as a predictive marker for extraprostatic extension of tumor in patients with clinically localized prostate cancer.
Salonia A
Eur Urol; 2008 Dec; 54(6):1331-2. PubMed ID: 18339473
[No Abstract] [Full Text] [Related]
2. Preoperative serum sex hormone-binding globulin as a predictive marker for extraprostatic extension of tumor in patients with clinically localized prostate cancer.
Lee SE; Chung JS; Han BK; Park CS; Moon KH; Byun SS; Choe G; Hong SK
Eur Urol; 2008 Dec; 54(6):1324-32. PubMed ID: 18339472
[TBL] [Abstract][Full Text] [Related]
3. Sex hormone-binding globulin: a novel marker for nodal metastases prediction in prostate cancer patients undergoing extended pelvic lymph node dissection.
Salonia A; Briganti A; Gallina A; Karakiewicz P; Shariat S; Freschi M; Zanni G; Capitanio U; Bosi E; Rigatti P; Montorsi F
Urology; 2009 Apr; 73(4):850-5. PubMed ID: 19038425
[TBL] [Abstract][Full Text] [Related]
4. Prediction of extraprostatic extension by prostate specific antigen velocity, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
Nishimoto K; Nakashima J; Hashiguchi A; Kikuchi E; Miyajima A; Nakagawa K; Ohigashi T; Oya M; Murai M
Int J Urol; 2008 Jun; 15(6):520-3. PubMed ID: 18422574
[TBL] [Abstract][Full Text] [Related]
5. Radial distance of extraprostatic extension measured by an ocular micrometer is an independent predictor of prostate-specific antigen recurrence: a new proposal for the substaging of pT3a prostate cancer.
Epstein JI
Am J Surg Pathol; 2008 Feb; 32(2):337-8; author reply 338-40. PubMed ID: 18223339
[No Abstract] [Full Text] [Related]
6. Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer.
Naito S; Kuroiwa K; Kinukawa N; Goto K; Koga H; Ogawa O; Murai M; Shiraishi T;
J Urol; 2008 Sep; 180(3):904-9; discussion 909-10. PubMed ID: 18635221
[TBL] [Abstract][Full Text] [Related]
7. Prediction of extraprostatic extension in men with biopsy Gleason score of 8 or greater.
Nakanishi H; Troncoso P; Babaian RJ
J Urol; 2008 Dec; 180(6):2441-5; discussion 2445-6. PubMed ID: 18930495
[TBL] [Abstract][Full Text] [Related]
8. Absence of relationship between steroid hormone levels and prostate cancer tumor grade.
Sher DJ; Mantzoros C; Jacobus S; Regan MM; Lee GS; Oh WK
Urology; 2009 Feb; 73(2):356-61; discussion 361-2. PubMed ID: 19036418
[TBL] [Abstract][Full Text] [Related]
9. Editorial Comment to Development and internal validation of a nomogram predicting extracapsular extension in radical prostatectomy specimens.
Tanaka N
Int J Urol; 2010 Mar; 17(3):272-3. PubMed ID: 20132360
[No Abstract] [Full Text] [Related]
10. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.
Whitman EJ; Groskopf J; Ali A; Chen Y; Blase A; Furusato B; Petrovics G; Ibrahim M; Elsamanoudi S; Cullen J; Sesterhenn IA; Brassell S; Rittenhouse H; Srivastava S; McLeod DG
J Urol; 2008 Nov; 180(5):1975-8; discussion 1978-9. PubMed ID: 18801539
[TBL] [Abstract][Full Text] [Related]
11. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
Milanese G; Dellabella M; Fazioli F; Pierpaoli E; Polito M; Siednius N; Montironi R; Blasi F; Muzzonigro G
J Urol; 2009 Mar; 181(3):1393-400. PubMed ID: 19157433
[TBL] [Abstract][Full Text] [Related]
12. [Plasma testosterone and sex hormone transport globulin in patients with prostatic carcinoma under treatment].
Daponte DP; Pidcock M; Robinson MR; Smith PH
Actas Urol Esp; 1982; 6(1):17-20. PubMed ID: 7200715
[No Abstract] [Full Text] [Related]
13. Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer.
Gupta A; Karakiewicz PI; Roehrborn CG; Lotan Y; Zlotta AR; Shariat SF
Clin Cancer Res; 2008 Nov; 14(22):7385-90. PubMed ID: 19010854
[TBL] [Abstract][Full Text] [Related]
14. Editorial comment on: prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.
Malavaud B
Eur Urol; 2008 Sep; 54(3):515-6. PubMed ID: 18585850
[No Abstract] [Full Text] [Related]
15. Editorial comment on: prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.
Rittmaster R
Eur Urol; 2008 Sep; 54(3):514-5. PubMed ID: 18585846
[No Abstract] [Full Text] [Related]
16. Editorial comment on: preliminary results of a novel method to estimate the probability of prostate cancer in men with elevated serum PSA values.
Chun FK; Briganti A
Eur Urol; 2008 Sep; 54(3):702. PubMed ID: 18403097
[No Abstract] [Full Text] [Related]
17. PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness.
Loeb S; Sutherland DE; D'Amico AV; Roehl KA; Catalona WJ
Urology; 2008 Nov; 72(5):1116-20; discussion 1120. PubMed ID: 18571700
[TBL] [Abstract][Full Text] [Related]
18. The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers.
Kehinde EO; Maghrebi MA; Anim JT
Can J Urol; 2008 Apr; 15(2):3967-74. PubMed ID: 18405443
[TBL] [Abstract][Full Text] [Related]
19. It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer.
Thompson IM; Ankerst DP; Etzioni R; Wang T
J Urol; 2008 Oct; 180(4):1219-22. PubMed ID: 18707707
[No Abstract] [Full Text] [Related]
20. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.
Gupta A; Lotan Y; Ashfaq R; Roehrborn CG; Raj GV; Aragaki CC; Montorsi F; Shariat SF
Eur Urol; 2009 May; 55(5):1124-33. PubMed ID: 18585843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
